The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2024 | Diminished chronic GvHD symptoms following anti-CD19 CAR T-cell therapy: a case study
Anna Czyz, MD, PhD, Wroclaw Medical University, Wroclaw, Poland, presents a case study of a patient with diffuse large B-cell lymphoma (DLBCL) who experienced resolution of chronic graft-versus-host disease (GvHD) symptoms following anti-CD19 CAR T-cell infusion. Along with other similar cases reported in the literature, this suggests that anti-CD19 CAR-T therapy may hold the potential for safely and effectively treating GvHD and immune-mediated diseases. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
